Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group.
Kobayashi T, et al. Among authors: matsumoto t.
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437. doi: 10.1016/S2468-1253(21)00062-5. Epub 2021 Apr 20.
Lancet Gastroenterol Hepatol. 2021.
PMID: 33887262
Clinical Trial.